Jacob Sands, MD - Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Land

Go online to PeerView.com/JCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape. Upon completion of this activity, participants should be better able to: Describe the current recommendations for diagnosis, staging, and appropriate evaluation of patients with SCLC throughout the disease course, Characterize the mechanisms of action and rationale for use of new/emerging therapies, including novel transcription inhibitors, for SCLC, Analyze the efficacy and safety data from the latest clinical trials evaluating standard, new, and emerging systemic therapies for SCLC, Integrate latest therapies into individualized treatment plans for appropriate patients with SCLC in the setting of clinical practice or clinical trial participation.